Mahana Therapeutics

The company’s lead product, "Mahana IBS," is an FDA-cleared prescription digital therapeutic program that delivers cognitive behavioral therapy to help patients manage irritable bowel syndrome. Clinical trials have demonstrated its effectiveness in improving symptoms and quality of life.

The company emphasizes rigorous clinical validation and regulatory clearance. In August 2023, Mahana entered a multi-million-dollar commercialization partnership with Bayer to expand access to its digital therapeutics. Additional programs targeting Crohn's disease and ulcerative colitis are under development. The company has locations in San Francisco, CA and London, UK. It remains privately held with backing from leading venture capital firms including Lux Capital. No public revenue or employee figures are available. Key partnerships include Bayer for commercialization/distribution of their lead product. Founded by Rob Paull and Simon Levy in 2018; current CEO not specified but founders are key people listed.